Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: A pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus claush in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalTherapeutics and Clinical Risk Management
Volume3
Issue number1
DOIs
Publication statusPublished - 2007

Fingerprint

Bacilli
Spores
Respiratory Tract Infections
Child Day Care Centers
Control Groups
Probiotics
day care
Bacillus
Milk
Bacillus clausii
Safety
Group
Therapeutics
evidence

Keywords

  • Allergy
  • Children
  • Probiotic
  • Respiratory infections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children : A pilot study. / Marseglia, Gian Luigi; Tosca, Mariangela; Cirillo, Ignazio; Licari, Amelia; Leone, Maddalena; Marseglia, Alessia; Castellazzi, Anna Maria; Ciprandi, Giorgio.

In: Therapeutics and Clinical Risk Management, Vol. 3, No. 1, 2007, p. 13-17.

Research output: Contribution to journalArticle

Marseglia, Gian Luigi ; Tosca, Mariangela ; Cirillo, Ignazio ; Licari, Amelia ; Leone, Maddalena ; Marseglia, Alessia ; Castellazzi, Anna Maria ; Ciprandi, Giorgio. / Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children : A pilot study. In: Therapeutics and Clinical Risk Management. 2007 ; Vol. 3, No. 1. pp. 13-17.
@article{a2a574f3429749d38f3bd2d5138b6e03,
title = "Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: A pilot study",
abstract = "Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus claush in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.",
keywords = "Allergy, Children, Probiotic, Respiratory infections",
author = "Marseglia, {Gian Luigi} and Mariangela Tosca and Ignazio Cirillo and Amelia Licari and Maddalena Leone and Alessia Marseglia and Castellazzi, {Anna Maria} and Giorgio Ciprandi",
year = "2007",
doi = "10.2147/tcrm.2007.3.1.13",
language = "English",
volume = "3",
pages = "13--17",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children

T2 - A pilot study

AU - Marseglia, Gian Luigi

AU - Tosca, Mariangela

AU - Cirillo, Ignazio

AU - Licari, Amelia

AU - Leone, Maddalena

AU - Marseglia, Alessia

AU - Castellazzi, Anna Maria

AU - Ciprandi, Giorgio

PY - 2007

Y1 - 2007

N2 - Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus claush in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

AB - Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus claush in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

KW - Allergy

KW - Children

KW - Probiotic

KW - Respiratory infections

UR - http://www.scopus.com/inward/record.url?scp=34247639971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247639971&partnerID=8YFLogxK

U2 - 10.2147/tcrm.2007.3.1.13

DO - 10.2147/tcrm.2007.3.1.13

M3 - Article

C2 - 18360611

AN - SCOPUS:34247639971

VL - 3

SP - 13

EP - 17

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -